Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-07-24
2007-07-24
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S422000, C546S196000, C548S525000
Reexamination Certificate
active
10942519
ABSTRACT:
Benzopyranone Compounds having the following structure:wherein R1, R2, X, Y and n are as defined herein, are disclosed. The Benzopyranone Compounds are useful for treating or preventing a bone-resorbing disease, a neoplastic disease, arthritis, a disease exacerbated by the presence of estrogen or a disease improved by the presence of estrogen, comprising administering an effective amount of a Benzopyranone Compound to a patient in need of the treating or preventing; activating the function of estrogen receptor (“ER”) in a bone cell; inhibiting the function of ER in a cancer cell; inhibiting the expression of interleukin-6 (“IL-6”) in a cell; and inhibiting the growth of a neoplastic cell, comprising contacting the cell with an effective amount of a Benzopyranone Compound.
REFERENCES:
patent: 6291456 (2001-09-01), Stein et al.
patent: 6331562 (2001-12-01), Bhagwat
patent: 6620838 (2003-09-01), McKie et al.
patent: 2004/0225005 (2004-11-01), Friedman et al.
patent: WO 00/39120 (2000-07-01), None
Al-Saffar et al., 1996, “Assessment of the role of GM-CSF in the cellular transformation and the development of erosive lesions around orthopaedic implants”, Am J Clin Pathol. 105(5):628-639.
Alonzi et al., 1998, “Interleukin 6 is required for the development of collagen-induced arthritis”, J Exp Med. 187(4):461-468.
Barkhem et al., 1998, “Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists”, Mol Pharmacol. 54(1):105-112.
Bismar et al., 1995, “Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement”, J Clin Endocrinol Metab. 80(11):3351-3355.
Bodine et al., 1998, “Estrogen receptor-alpha is developmentally regulated during osteoblast differentiation and contributes to selective responsiveness of gene expression”, Endocrinology. 139(4):2048-2057.
Borsellino et al., “Therapeutic agents II (genes, gene components, antireceptors),” Proc. Annu. Meet. Am. Assoc. Cancer Res. 37(2801):410-411 (1996).
Brandenberger et al., 1998, “Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues”, J Clin Endocrinol Metab. 83(3):1025-1028.
Chen et al., 2001, “Molecular basis for the constitutive activity of estrogen-related receptor alpha-1”, J Biol Chem. 276(30):28465-470.
Chung et al., 2002, “Resisitance to tamoxifen-induced apoptosis is associated with direct interaction between Her2
eu and cell membrane estrogen receptor in breast cancer”, Int J Cancer. 97(3):306-312.
Clinton and Hua, 1997, “Estrogen action in human ovarian cancer”, Crit Rev Oncol Hematol. 25(1):1-9.
Cooke et al., 1998, “Mechanism of estrogen action: lessons from the estrogen receptor-alpha knockout mouse”, Biol Reprod. 59(3):470-475.
Couse et al., 1997, “Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse”, Endocrinology. 138(11):4613-4621.
Coward et al., 2001, “4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor gamma”, Proc Natl Acad Sci U S A. 98(15):8880-8884.
Das et al., 1997, “Estrogenic responses in estrogen receptor-α deficient mice reveal a distinct estrogen signaling pathway”, Proc. Natl. Acad. Sci. USA 94:12786-12791.
Devlin et al., 1998, “IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures”, J Bone Miner Res. Mar. 1998; 13(3):393-399.
Duan et al., 1998, “Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation”, Endocrinology. 139(4):1981-1990.
Enmark et al., 1997, “Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern”, J Clin Endocrinol Metab. 82(12):4258-4265.
Eustace et al., 1993, “Interleukin-6 (IL-6) functions as an autocrine growth factor in cervical carcinomas in vitro”, Gynecol Oncol. 50(1):15-19.
Farhat et al., 1996, “The vascular protective effects of estrogen”, FASEB J. 10(5):615-624.
Garrett et al., 1997, “A murine of human myeloma bone disease”, Bone 20(6):515-520.
Girasole et al., 1992, “17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens”, J Clin Invest. 89(3):883-891.
Grese et al., 1997, “Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene”, J Med Chem. 40(2):146-167.
Gupta et al., 1985, “7-hydroxy-4-phenyl-3(4-hydroxyohenyl)-coumarin—a new interceptive agent”, Indian J Exp Biol. 23(11):638-640.
Gustafsson et al., 1998, “Therapeutic potential of selective estrogen receptor modulators”, Curr Opin Chem Biol. 2(4):508-511.
Hata et al., 1998, “Role estrogen and estrogen-related growth factor in the mechanism of hormone dependency of endometrial carcinoma cells”, Oncology. 55 Suppl 1:35-43.
Hughes et al., 1996, “Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta”, Nat Med. 2(10):1132-1136.
Iafrati et al., 1997, “Estrogen inhibits the vascular injury response in estrogen receptor alpha-deficient mice”, Nat Med. 3(5):545-548.
Jansson et al., 1994, “Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice”, J Neuroimmunol. 53(2):203-207.
Jeltsch et al., 1987, “Structure of the human oestrogen-responsive gene pS2”, Nucleic Acids Res. 15(4):1401-1414.
Jilka et al., 1995, “Estrogen loss upregulates hematopoiesis in the mouse: a mediating role of IL-6”, Exp Hematol. 23(6):500-506.
Jilka et al., 1992, “Increased osteoclast development after estrogen loss: mediation by interleukin-6”, Science 57(5066):88-91.
Kelly et al., 1999, “Estrogen Modulation of G-protein-coupled Receptors”, Trends Endocrinol Metab. 10(9):369-374.
Kimble et al., 1996, “Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1 and tumor necrosisfactor-mediatedstimulation of macrophage colony-stimulating factor production”, J Biol Chem. 271(46):28890-28897.
Kimble et al., 1995, “Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period”, Endocrinology. 136(7):3054-3061.
Klein et al., 1991, “Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia”, Blood. 78(5):1198-1204.
Klein et al., 1989, “Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by Interleukin-6”, Blood. 73(2):517-526.
Koo et al., 1992, “ Interleukin-6 and renal cell cancer: production, regulation, and growth effects”, Cancer Immunol Immunother. 35(2):97-105.
Korach et al., 1994, “Insights from the study of animals lacking functional estrogen receptor”, Science 266(5190):1524-1527.
Krege et al., 1998, “Generation and reproductive phenotypes of mice lacking estrogen receptor beta”, Proc Natl Acad Sci U S A.95(26):15677-15682.
Kuiper et al., 1997, “Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta”, Endocrinology. Mar. 1997;138(3):863-870.
Kurihara et al., 1989, “Generation of osteoclasts from isolated hemat
Bhagwat Shripad S.
McKie Jeffrey A.
Missbach Martin
Renaud Johanne
Jones Day
Novartis AG
Powers Fiona T.
Signal Pharmaceuticals LLC
LandOfFree
Benzopyranone compounds, compositions thereof, and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzopyranone compounds, compositions thereof, and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzopyranone compounds, compositions thereof, and methods... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3733924